

U.S. Serial No. 10/047,072  
Response to Office Action mailed July 28, 2004

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): An *in vitro* method for producing dendritic cells from pluripotential cells, comprising:

a) contacting the pluripotential cells having the potential of expressing either macrophage or dendritic cell characteristics with one or more cytokines for a time sufficient to produce immature dendritic cells; and

b) contacting said immature dendritic cells with a factor for a time sufficient for the pluripotential immature dendritic cells to produce stable mature dendritic cells that and express a characteristic of mature dendritic cells,

wherein the characteristic[[s]] is selected from the group consisting of increased CD83 expression, increased CD86 expression, decreased CD115 expression, and decreased CD32 expression relative to the pluripotential immature dendritic cells; and said factor is present in peripheral blood mononuclear cell conditioned medium, monocyte conditioned medium or macrophage conditioned medium.

Claim 2 (original): The method of claim 1, wherein the pluripotential cells are CD14 positive mononuclear pluripotential cells.

Claim 3 (original): The method of claim 1, wherein the pluripotential cells are peripheral blood mononuclear cells.

Claim 4 (original): The method of claim 1, wherein the pluripotential cells are monocytes.

Claim 5 (original): The method of claim 1, wherein the factor comprises GM-CSF.

Claim 6 (original): The method of claim 5, wherein the factor further comprises a cytokine selected from the group consisting of IL-4; IL-13; IL-4 and IL-1 $\beta$ ; IL-13 and IL-1 $\beta$ ; IL-4 and

U.S. Serial No. 10/047,072  
Response to Office Action mailed July 28, 2004

TNF- $\alpha$ ; IL-13 and TNF- $\alpha$ ; IL-4, IL-1 $\beta$ , and TNF- $\alpha$ ; IL-13, IL-1 $\beta$ , and TNF- $\alpha$ ; IL-4 and IL-12; IL-13 and IL-12; IL-4 and stem cell factor, IL-13 and stem cell factor; IL-4 and IL-15; and IL-13 and IL-15.

Claims 7-9 (cancelled)

Claim 10 (previously presented): The method of claim 6, wherein the GM-CSF is present at a concentration of between about 200 U/ml to about 2000 U/ml.

Claim 11 (previously presented): The method of claim 1, wherein the dendritic cells express high levels of MHC class molecules.

Claim 12 (currently amended): The method of claim 1, wherein the dendritic cells have the capacity to stimulating stimulate resting T cells.